Neuravi is an early stage company in the large emerging acute ischemic stroke thrombectomy device market. The company designs and develops products for restoring blood flow in patients who have suffered ischemic strokes due to blockage of an artery to the brain. Neuravi was founded in 2009 and is headquartered in Galway, Ireland, home to many of the world’s leading medical device companies.
According to the American Heart Association, or AHA, stroke is the third leading cause of death and a leading cause of disability in the United States. Over 780,000 strokes occur annually in the US, and AHA estimates that the direct and indirect cost of stroke in 2008 was in excess of $65 billion.
Stroke becomes more common with age, and approximately 75% of strokes occur in people over the age of 65. In addition to increasing age, risk factors for stroke include diabetes, cardiovascular disease and obesity. Of all strokes in the United States, over 85% are ischemic, the result of a clot blocking blood flow in the vessels of the brain. Neuravi’s products are designed to restore blood flow to the brain by removing the clot that is causing the blood flow blockage.